Method for preparing medicine targeted controlled-release nano eyedrop

Abstract

The invention discloses a preparation method for drug targeting controlled release nano-particle eye drops, which pertains to the preparation methods of eye preparations. The invention firstly dissolves certain portions by weight of drug and biodegradable polymer in organic solvent so as to obtain solution A; additionally, certain portions by weight of cholesterol modified chitosan is dissolved in water, and solution B is obtained by stirring and rotating; the two are mixed and stirred till the organic solvent is fully volatilized; the drug-carrying polymer nanoparticles are obtained by centrifugal separation, water washing and drying; and then the eye drops are prepared by the general preparation method of the industry of eye drops. The eye drops which are prepared by the method of the invention can ensure the effective drug treatment concentration without the need of frequent and high-concentration drug delivery, can significantly prolong the eye surface acting time of the drug and release the drug continuously and constantly, the eye surface retention time of the drug-carrying particles of the eye drops can be up to six hours, the efficacy is improved and the side effects of the drug are reduced simultaneously.

Description

technical field [0001] The present invention relates to a preparation method of an ophthalmic preparation, or a medical preparation characterized by a special physical shape. Specifically, it is a method for preparing drug-targeted controlled-release nanoparticle eye drops, Background technique [0002] The treatment of many eye diseases, especially the treatment of anterior segment diseases, requires that the therapeutic drug can reach an effective therapeutic concentration and continue to act on the eye. Although systemic administration can also effectively treat eye diseases, it often causes serious adverse reactions, such as liver and kidney damage. Although traditional eye drops have become the preferred dosage form for ophthalmic clinical external use due to their advantages of convenient use and good patient acceptance, but when administered locally, reflex tear secretion and nasolacrimal duct drainage usually occur after 4 minutes of eye drops. , the drug is only 5...

AI Technical Summary

Problems solved by technology

Although systemic administration can also effectively treat eye diseases, it often causes serious adverse reactions, such as liver and kidney damage, etc.

Although traditional eye drops have become the preferred dosage form for ophthalmic clinical external use due to their advantages of convenient use and good patient acceptance, but when administered locally, reflex tear secretion and nasolacrimal duct drainage usually occur after 4 minutes of eye drops. , the drug is only 50% in the conjunctival sac, and only 17% remains after 10 minutes, which is far below the effective therapeutic concentration, so frequent and high-concentration administration is required

Images